NAMD notified the Center for Medicare and Medicaid Services (CMS), of its strong support for a next generation SIM initiative to continue building state capacity to lead the movement to a value-based health care system. Read full letter.
In its response to a federal request for input, NAMD aligns with CMS’s goal to enhance the efficiency and effectiveness of the federal process for developing and acquiring technology and systems to support the Medicaid program. Read full letter.
NAMD provided comments to leaders of the House Energy and Commerce Committee on their draft proposal to establish a pediatric health home option for Medicaid children with medically complex conditions. Read full letter.
NAMD submitted comments to CMS on the proposed rule implementing the Merit-based Incentive Payment System and Advanced Alternative Payment Model (APM) programs, which were created under the Medicare Access and CHIP Reauthorization Act of 2015. NAMD’s comments discuss the impact of the rule on state Medicaid payment and delivery system reform, and explore unique Medicaid […]
NAMD partnered with the National Association of States United for Aging and Disability (NASUAD), the National Association of State Directors of Developmental Disabilities Services (NASDDDS), and the National Association of State Mental Health Program Directors (NASMHPD) to send a joint letter to the Department of Labor (DOL). The letter outlines the state associations’ concerns with […]
NAMD submitted comments to the Health Care Payment Learning Action Network on its draft white paper on clinical episode payment for maternity care. The comments highlight state Medicaid considerations when designing a clinical episode payment model for maternity care. Read full letter.
On May 18, NAMD submitted comments to the Health Resources and Services Administration (HRSA) in response to reopened provisions of a proposed rule on the 340B drug discount program. NAMD called for HRSA to maintain its initially proposed “penny pricing” method for 340B drugs, for HRSA to align the 340B ceiling price for new drugs […]